AL | AN | |
---|---|---|
Plasmodium falciparum | ||
Per protocol (total = 186) | ||
Number | 92 | 94 |
Successes (proportion) | 0.978 | 1.00 |
Mean cost (US$)/patient | 7.66 | 17.28 |
Incremental successes | – | 0.022 |
Incremental costs (US$) | – | 9.61 |
Incremental cost-effectiveness ratio | – | 436.82 |
Modified intention to treat (N = 198) | ||
Number | 100 | 98 |
(i) Worst case | ||
Successes (proportion) | 0.900 | 0.959 |
Mean cost (US$)/patient | 7.55 | 17.16 |
Incremental successes | – | 0.059 |
Incremental costs (US$) | – | 9.60 |
Incremental cost-effectiveness ratio | – | 162.71 |
(ii) Best case | ||
Successes (proportion) | 0.980 | 1.000 |
Mean cost (US$)/patient | 7.55 | 17.16 |
Incremental successes | – | 0.020 |
Incremental costs (US$) | – | 9.60 |
Incremental cost-effectiveness ratio | – | 480.00 |
Plasmodium vivax | ||
Per protocol (total = 46) | ||
Number | 20 | 26 |
Successes (proportion) | 0.300 | 1.000 |
Mean cost (US$)/patient | 7.41 | 17.78 |
Incremental successes | – | 0.700 |
Incremental costs (US$) | – | 10.38 |
Incremental cost-effectiveness ratio | – | 14.83 |
Modified intention to treat (N = 47) | ||
Number | 20 | 27 |
(i) Worst case | ||
Successes (proportion) | 0.300 | 0.963 |
Mean cost (US$)/patient | 7.41 | 17.52 |
Incremental successes | – | 0.663 |
Incremental costs (US$) | – | 10.11 |
Incremental cost-effectiveness ratio | – | 15.25 |
(ii) Best case | ||
Successes (proportion) | 0.300 | 1.000 |
Mean cost (US$)/patient | 7.41 | 17.52 |
Incremental successes | – | 0.700 |
Incremental costs (US$) | – | 10.11 |
Incremental cost-effectiveness ratio | – | 14.29 |